He Min, Ren Siyu, Lin Yongqi, Zeng Xiaocong
Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Guangxi Key Laboratory Base of Precision Medicine in Cardiocerebrovascular Diseases Control and Prevention & Guangxi Clinical Research Center for Cardio-Cerebrovascular Diseases, Nanning, Guangxi, China.
Front Cardiovasc Med. 2024 May 31;11:1371000. doi: 10.3389/fcvm.2024.1371000. eCollection 2024.
The adverse clinical endpoints of cardiovascular and kidney diseases are correlated with increased serum phosphate levels. However, in critically ill patients with coronary heart disease (CHD) accompanied by chronic kidney disease (CKD), the prognostic value of serum phosphate remains unclear.
Patients' medical records from the Medical Information Mart for Intensive Care IV database who had concomitant CKD and CHD were classified into four distinct groups in this large retrospective observational cohort study based on the quartiles of serum phosphate levels. Vital status and the duration of hospital and ICU stays within the short-term follow-up periods of 30 and 90 days constituted the primary outcomes. All-cause mortality in the intensive care unit (ICU) and hospital constituted the secondary outcomes. Further, the Cox proportional hazard and restricted cubic spline (RCS) regression models were employed to ascertain how serum phosphate levels correlated with the primary outcomes. In addition, the occurrence rate of the secondary outcomes across the four quartiles was determined utilizing the Kaplan-Meier method.
Among the total 3,557 patients (67.6% male) included, the hospital and ICU all-cause mortality rates were 14.6% and 10%, separately. Higher quartiles of serum phosphate concentrations were associated with shorter short-term survival rates, as shown by the Kaplan-Meier curves. Additionally, the Cox proportional hazards analysis illustrated that serum phosphate was independently linked to a higher death risk in the hospital [HR, 1.10 (95% CI: 1.03-1.18), = 0.007] and ICU [HR, 1.14 (95% CI: 1.07-1.22), < 0.001]. Lastly, the RCS regression models suggested a robust non-linear correlation between serum phosphate concentrations and death risk in the ICU and hospital (both for non-linearity <0.001).
The prognostic value of serum phosphate is significant in critically ill patients with CHD accompanied by CKD. Furthermore, serum phosphate is potentially valuable for identifying patients with this concomitant condition.
心血管疾病和肾脏疾病的不良临床终点与血清磷酸盐水平升高相关。然而,在患有冠心病(CHD)并伴有慢性肾脏病(CKD)的重症患者中,血清磷酸盐的预后价值仍不明确。
在这项大型回顾性观察队列研究中,根据血清磷酸盐水平的四分位数,将来自重症监护医学信息数据库IV中患有CKD和CHD的患者分为四个不同的组。在30天和90天的短期随访期内的生命状态以及住院和ICU住院时间构成主要结局。重症监护病房(ICU)和医院的全因死亡率构成次要结局。此外,采用Cox比例风险模型和限制立方样条(RCS)回归模型来确定血清磷酸盐水平与主要结局之间的相关性。另外,利用Kaplan-Meier方法确定四个四分位数中次要结局的发生率。
在纳入的总共3557例患者中(男性占67.6%),医院和ICU的全因死亡率分别为14.6%和10%。Kaplan-Meier曲线显示,血清磷酸盐浓度较高的四分位数与较短的短期生存率相关。此外,Cox比例风险分析表明,血清磷酸盐与医院死亡风险较高独立相关[风险比(HR),1.10(95%置信区间:1.03-1.18),P = 0.007]和ICU死亡风险较高独立相关[HR,1.14(95%置信区间:1.07-1.22),P < 0.001]。最后,RCS回归模型表明血清磷酸盐浓度与ICU和医院的死亡风险之间存在强烈的非线性相关性(两者的非线性P均<0.001)。
血清磷酸盐在患有CHD并伴有CKD的重症患者中具有显著的预后价值。此外,血清磷酸盐对于识别患有这种合并症的患者可能具有重要价值。